Malvern Instruments increases its research portfolio

First published in News
Last updated

TECHNOLOGY innovator Malvern Instruments is expanding.

The company on Enigma Business Park has acquired the MicroCal™ microcalorimetry business of GE Healthcare Life Sciences of Little Chalfont, Buckinghamshire.

Financial terms were not disclosed and the acquisition, which is subject to regulatory approvals, is expected to complete in the third quarter of 2014.

MicroCal has a 30-year history of developing and supplying easy-to-use microcalorimeters.

These systems are used extensively to study proteins and other biomolecules in drug discovery and development.

The acquisition of MicroCal will further strengthen Malvern’s rapidly expanding portfolio of analytical solutions for customers in core pharmaceutical and biopharmaceutical markets.

Paul Walker, managing director of Malvern Instruments, said: “Microcalorimetry is now an essential tool that is used at almost every stage of the drug discovery, development and formulation process.

MicroCal is an established technology leader in the field and MicroCal products are an excellent fit with Malvern’s existing portfolio of measurement solutions for the pharmaceutical and biopharmaceutical industries.

This addition to our business will have an immediate impact on Malvern’s ability to provide a complete range of instrumentation solutions and support across life science research and development."

Although headquartered in the UK, Malvern Instruments is a global business that serves a diverse range of academic and industrial markets, providing instrumentation for the analysis of a wide variety of materials. The company is part of the Materials Analysis Division of Spectris plc.

Comments

Comments are closed on this article.

Send us your news, pictures and videos

Most read stories

Local Info

Enter your postcode, town or place name

About cookies

We want you to enjoy your visit to our website. That's why we use cookies to enhance your experience. By staying on our website you agree to our use of cookies. Find out more about the cookies we use.

I agree